Cancer Therapy-Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies

被引:199
作者
Hahn, Virginia Shalkey [1 ]
Lenihan, Daniel J. [4 ]
Ky, Bonnie [1 ,2 ,3 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Penn Cardiovasc Inst, Philadelphia, PA 19104 USA
[3] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[4] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2014年 / 3卷 / 02期
基金
美国国家卫生研究院;
关键词
anthracycline cardiotoxicity; cardio-oncology; cardiotoxicity; sunitinib cardiotoxicity; trastuzumab cardiotoxicity; ANTHRACYCLINE-INDUCED CARDIOTOXICITY; ACTIVATED PROTEIN-KINASE; CONGESTIVE-HEART-FAILURE; DOXORUBICIN-INDUCED CARDIOTOXICITY; CONVERTING ENZYME-INHIBITION; 3RD-GENERATION BETA-BLOCKER; IMPROVES CARDIAC-FUNCTION; EARLY BREAST-CANCER; ADJUVANT TRASTUZUMAB; INDUCED CARDIOMYOPATHY;
D O I
10.1161/JAHA.113.000665
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mechanisms of cancer therapy-induced cardiotoxicity include a combination of on-target effects on signaling cascades essential to both cancer progression and normal cardiac function and off-target effects due to nonselective actions. Effective therapies to treat cancer and cancer therapy- induced cardiotoxicity must either take advantage of tissuespecific differences or affect the downstream mediators of toxicity, and there are active studies under way to develop new targeted therapies.140,141 Other effective therapies for cardioprotection include typical pharmacologic therapies used in cardiovascular disease that promote increased cardiac reserve and reverse remodeling under the stress of cancer therapy. Most of the data regarding mechanisms of cardiotoxicity due to cancer therapy have been obtained from animal models of this disease process; therefore, further studies to improve our understanding of the relevance of these pathways in humans are necessary. © 2014 The Authors.
引用
收藏
页数:14
相关论文
共 141 条
[31]   Anthracycline Cardiomyopathy Is Mediated by Depletion of the Cardiac Stem Cell Pool and Is Rescued by Restoration of Progenitor Cell Function [J].
De Angelis, Antonella ;
Piegari, Elena ;
Cappetta, Donato ;
Marino, Laura ;
Filippelli, Amelia ;
Berrino, Liberato ;
Ferreira-Martins, Joao ;
Zheng, Hanqiao ;
Hosoda, Toru ;
Rota, Marcello ;
Urbanek, Konrad ;
Kajstura, Jan ;
Leri, Annarosa ;
Rossi, Francesco ;
Anversa, Piero .
CIRCULATION, 2010, 121 (02) :276-U188
[32]   Management of Antiangiogenic Therapy-Induced Hypertension [J].
de Jesus-Gonzalez, Nilka ;
Robinson, Emily ;
Moslehi, Javid ;
Humphreys, Benjamin D. .
HYPERTENSION, 2012, 60 (03) :607-615
[33]   Endothelial β3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation β-blocker nebivolol [J].
Dessy, C ;
Saliez, J ;
Ghisdal, P ;
Daneau, G ;
Lobysheva, II ;
Frérart, F ;
Belge, C ;
Jnaoui, K ;
Noirhomme, P ;
Feron, O ;
Balligand, JL .
CIRCULATION, 2005, 112 (08) :1198-1205
[34]   Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors [J].
Dirix, L. Y. ;
Maes, H. ;
Sweldens, C. .
ANNALS OF ONCOLOGY, 2007, 18 (06) :1121-1122
[35]   EFFECT OF BETA-ADRENERGIC-BLOCKADE ON MYOCARDIAL-FUNCTION AND ENERGETICS IN CONGESTIVE HEART-FAILURE - IMPROVEMENTS IN HEMODYNAMIC, CONTRACTILE, AND DIASTOLIC PERFORMANCE WITH BUCINDOLOL [J].
EICHHORN, EJ ;
BEDOTTO, JB ;
MALLOY, CR ;
HATFIELD, BA ;
DEITCHMAN, D ;
BROWN, M ;
WILLARD, JE ;
GRAYBURN, PA .
CIRCULATION, 1990, 82 (02) :473-483
[36]   Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats [J].
El-Aziz, MAA ;
Othman, AI ;
Amer, M ;
El-Missiry, MA .
JOURNAL OF APPLIED TOXICOLOGY, 2001, 21 (06) :469-473
[37]   The β-blocker Nebivolol Is a GRK/β-arrestin Biased Agonist [J].
Erickson, Catherine E. ;
Gul, Rukhsana ;
Blessing, Christopher P. ;
Jenny Nguyen ;
Liu, Tammy ;
Pulakat, Lakshmi ;
Bastepe, Murat ;
Jackson, Edwin K. ;
Andresen, Bradley T. .
PLOS ONE, 2013, 8 (08)
[38]   Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology [J].
Eschenhagen, Thomas ;
Force, Thomas ;
Ewer, Michael S. ;
de Keulenaer, Gilles W. ;
Suter, Thomas M. ;
Anker, Stefan D. ;
Avkiran, Metin ;
de Azambuja, Evandro ;
Balligand, Jean-Luc ;
Brutsaert, Dirk L. ;
Condorelli, Gianluigi ;
Hansen, Arne ;
Heymans, Stephane ;
Hill, Joseph A. ;
Hirsch, Emilio ;
Hilfiker-Kleiner, Denise ;
Janssens, Stefan ;
de Jong, Steven ;
Neubauer, Gitte ;
Pieske, Burkert ;
Ponikowski, Piotr ;
Pirmohamed, Munir ;
Rauchhaus, Mathias ;
Sawyer, Douglas ;
Sugden, Peter H. ;
Wojta, Johann ;
Zannad, Faiez ;
Shah, Ajay M. .
EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (01) :1-10
[39]   Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment [J].
Ewer, MS ;
Vooletich, MT ;
Durand, JB ;
Woods, ML ;
Davis, JR ;
Valero, V ;
Lenihan, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :7820-7826
[40]   Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines [J].
Fazel, Shafie ;
Cimini, Massimo ;
Chen, Liwen ;
Li, Shuhong ;
Angoulvant, Denis ;
Fedak, Paul ;
Verma, Subodh ;
Weisel, Richard D. ;
Keating, Armand ;
Li, Ren-Ke .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (07) :1865-1877